Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive malignancy in which the tumors lack expression of estrogen receptor, progesterone receptor and HER2. Hence, TNBC patients cannot benefit from clinically available targeted therapies and rely on chemotherapy and surgery for treatment. While initia...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer Ther
Main Authors: Jabbour-Leung, Natalie A., Chen, Xian, Bui, Tuyen, Jiang, Yufeng, Yang, Dong, Vijayaraghavan, Smruthi, McArthur, Mark J., Hunt, Kelly K., Keyomarsi, Khandan
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4873336/
https://ncbi.nlm.nih.gov/pubmed/26826118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0519
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items